632. 58. Solca F, Rudolph D, Guertler U. Targeting the M phase: Focus on PLK 1 and aurora B. J Thoracic Oncol. 2010, 5 abstr 28IN . 59. Mross KB, Scheulen ME, Frost A, et al. A phase I dose escalation study of BI 811283, an aurora B inhibitor, administered every three weeks in patients with advanced BMS-582664 Brivanib alaninate solid tumors. J Clin Oncol. 2010, 28 abstr 3011. 60. Scheulen ME, Mross KB, Richly H, et al. A phase I dose escalation study of BI 811283, an aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol. 2010, 28 abstr e13065. 61. Gully CP, Zhang F, Chen J, et al. Antineoplastic effects of an aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010, 9:42 54. 62. Azzariti A, Porcelli L, Simone G, et al.
Aurora kinase inhibitor AZD1152 inhibits cell growth, induces apoptosis and enhances chemotherapeutics, activity in various cancer in vitro models. Proc Am Assoc Cancer Res. 2007, 48 abstr 4359. 63. Wilkinson RW, Keen N, Odedra R, et al. AZD1152: a highly potent and specific aurora kinase inhibitor. Proc Am Assoc Cancer Res. BI 2536 2006, 47 abstr 5673. 64. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007, 13: 3682 8. 65. Goodlad RA, Alferez D, Ryan A, et al. Targeting aurora B kinase activity with AZD1152 leads to antitumor effects in preclinical models of intestinal cancer. Proc Am Assoc Cancer Res. 2007, 48 abstr 1640. 66. Nair J, Schwartz G.
A selective aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with irinotecan in colon cancer cells. Proc Am Assoc Cancer Res. 2008, 49 abstr 5645. 67. Helfrich B, Theodoro M, Varella Garcia M, et al. The selective aurora B kinase inhibitor AZD1152 HQPA inhibits in vitro growth of small cell lung cancer cell lines. Proc Am Assoc Cancer Res. 2009, 50 abstr 4775. 68. Aihara A, Tanaka S, Yasen M, et al. The selective aurora B kinase inhibitor AZD 1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010, 52:63 71. 69. Betta P, Bensi T, Trincheri NF, et al. Aurora B kinase and malignant mesothelioma. J Clin Oncol. 2010, 28 abstr e21021. 70. Oke A, Pearce D, Wilkinson RW, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Cancer Res. 2009, 69: 4150 8. Green et al. Page 17 Expert Opin Drug Discov. Author manuscript, available in PMC 2012 March 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 71. Walsby E, Walsh V, Pepper C, et al. The aurora kinase inhibitor AZD1152 causes perturbation of cell cycle distribution in cell lines and primary AML samples. Blood . 2005, 106 abstr 2759. 72. Pearce D, Odedra R, Wilkinson R, Bonnet D. The specific aurora kinase inhibitor AZD1152 significantly affects the growth of human leukaemic cells in an in vivo AML model. Blood . 2006, 108 abstr 162. 73. Evans RP, Naber C, Steffler T, et al. The selective aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 2007, 140:295 302. 74.
Grundy M, Seedhouse C, Shang S, et al. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD 1152 HQPA in acute myelogenous leukemia cells. Mol Cancer Ther. 2010, 9:661 72. 75. Yang J, Ikezoe R, Nichioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007, 110:2034 40. 76. Tao Y, Leteur C, Calderaro J, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle. 2009, 8:3172 81. 77. Walsby E, Walsh V, Pepper C, et al. Effects of the aurora kinase inhibitors AZD1152 HQPA a